New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 15, 2014
14:19 EDTXLRN, CELGCelgene, Acceleron announce interim data from beta-thalassemia study
Celgene (CELG) and Acceleron Pharma (XLRN) announced interim data from two studies of candidates from the companiesí joint development program in beta-thalassemia. The data presented at the 19th European Hematology Association, EHA, annual congress show activity for two programs, sotatercept and ACE-536, in patients with both transfusion dependent and non-transfusion dependent beta-thalassemia. There is currently no drug approved to treat beta-thalassemia. Both sotatercept and ACE-536 have been granted orphan drug designation for beta-thalassemia by the FDA.
News For CELG;XLRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
07:12 EDTCELGWilliam Blair names 21 stocks best positioned for volatile markets
Subscribe for More Information
August 27, 2015
16:03 EDTCELGCelgene completes acquisition of Receptos
Subscribe for More Information
August 25, 2015
07:31 EDTCELGCelgene announces expiration of tender offer for Receptos shares
Subscribe for More Information
August 24, 2015
18:55 EDTCELGOn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTCELGJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
13:36 EDTCELGBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.
August 23, 2015
12:35 EDTCELGBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use